JO3408B1 - مركبات بترين سلفون اميد ثيازول و أوكسازول - Google Patents

مركبات بترين سلفون اميد ثيازول و أوكسازول

Info

Publication number
JO3408B1
JO3408B1 JOP/2009/0162A JOP20090162A JO3408B1 JO 3408 B1 JO3408 B1 JO 3408B1 JO P20090162 A JOP20090162 A JO P20090162A JO 3408 B1 JO3408 B1 JO 3408B1
Authority
JO
Jordan
Prior art keywords
benzene sulfonamide
oxazole compounds
thiazole
sulfonamide thiazole
oxazole
Prior art date
Application number
JOP/2009/0162A
Other languages
English (en)
Inventor
W Johnson Neil
Howard Dickerson Scott
Wilson Brian
Leroy Adams Jerry
Stellwagen John
Petrov Kimberly
Schaaf Gregory
Edward Uehling David
Gregory Waterson Alex
M Ralph Jeffrey
Tian Xinrong
Renae Rheault Tara
Kuntz Kevin
Original Assignee
Novartis Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=41265326&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=JO3408(B1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Novartis Ag filed Critical Novartis Ag
Application granted granted Critical
Publication of JO3408B1 publication Critical patent/JO3408B1/ar

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425—Thiazoles
    • A61K31/427—Thiazoles not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Oncology (AREA)
  • Hematology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Thiazole And Isothizaole Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)

Abstract

يتعلق الاختراع الحالي بتوفير مركبات ثيازول سلفوناميد و أوكسازول سلفوناميد، وتركيبات تحتوي على ثيازول سلفوناميد و أوكسازول سلفوناميد. كما يتعلق الاختراع الحالي بعمليات لتحضيرها وطرق لاستخدامها كعوامل صيدلانية.
JOP/2009/0162A 2008-05-06 2009-05-04 مركبات بترين سلفون اميد ثيازول و أوكسازول JO3408B1 (ar)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US5074408P 2008-05-06 2008-05-06

Publications (1)

Publication Number Publication Date
JO3408B1 true JO3408B1 (ar) 2019-10-20

Family

ID=41265326

Family Applications (1)

Application Number Title Priority Date Filing Date
JOP/2009/0162A JO3408B1 (ar) 2008-05-06 2009-05-04 مركبات بترين سلفون اميد ثيازول و أوكسازول

Country Status (34)

Country Link
US (6) US7994185B2 (ar)
EP (2) EP3106462A1 (ar)
JP (1) JP5426664B2 (ar)
KR (1) KR101628746B1 (ar)
CN (1) CN102083312B (ar)
AR (1) AR071617A1 (ar)
AU (1) AU2009244491B2 (ar)
BR (1) BRPI0912541B8 (ar)
CA (1) CA2723396C (ar)
CL (1) CL2009001065A1 (ar)
CO (1) CO6321189A2 (ar)
CY (1) CY1117615T1 (ar)
DK (1) DK2282636T3 (ar)
DO (1) DOP2010000326A (ar)
EA (1) EA019349B1 (ar)
ES (1) ES2576684T3 (ar)
HR (1) HRP20160447T1 (ar)
HU (1) HUE028820T2 (ar)
IL (1) IL209018A (ar)
JO (1) JO3408B1 (ar)
MA (1) MA32369B1 (ar)
MX (1) MX2010012074A (ar)
MY (1) MY155317A (ar)
NZ (1) NZ588970A (ar)
PE (1) PE20091952A1 (ar)
PL (1) PL2282636T3 (ar)
RS (1) RS54725B1 (ar)
SG (1) SG190624A1 (ar)
SI (1) SI2282636T1 (ar)
TW (1) TWI432430B (ar)
UA (1) UA103319C2 (ar)
UY (1) UY31806A (ar)
WO (1) WO2009137391A2 (ar)
ZA (1) ZA201007960B (ar)

Families Citing this family (104)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2008063888A2 (en) 2006-11-22 2008-05-29 Plexxikon, Inc. Compounds modulating c-fms and/or c-kit activity and uses therefor
MX2010000617A (es) 2007-07-17 2010-05-17 Plexxikon Inc Compuestos y metodos para modulacion de cinasa, e indicaciones de estos.
MX2010009410A (es) * 2008-02-29 2010-11-30 Array Biopharma Inc Compuestos del inhibidor de raf y métodos de uso de los mismos.
US20110003859A1 (en) * 2008-02-29 2011-01-06 Array Biopharma Inc. N- (6-aminopyridin-3-yl) -3- (sulfonamido) benzamide derivatives as b-raf inhibitors for the treatment of cancer
CL2009000448A1 (es) * 2008-02-29 2009-11-27 Genentech Inc Compuestos derivados de 3-sulfonilamino-n-(1h-pirazolo-[3,4-b]piridin-5il)benzamida; procesos de preparacion; compuestos intermediarios; composicion farmaceutica; y uso para el tratamiento del cancer, tal como sarcoma, carcinoma, adenoma, entre otros.
JP2011513329A (ja) * 2008-02-29 2011-04-28 アレイ バイオファーマ、インコーポレイテッド ＲＡＦ阻害化合物として使用されるイミダゾ［４，５−ｂ］ピリジン誘導体
UA103319C2 (en) * 2008-05-06 2013-10-10 Глаксосмитклайн Ллк Thiazole- and oxazole-benzene sulfonamide compounds
WO2010104899A1 (en) * 2009-03-12 2010-09-16 Glaxosmithkline Llc Thiazole sulfonamide and oxazole sulfonamide kinase inhibitors
EA031116B1 (ru) 2009-04-03 2018-11-30 Ф. Хоффманн-Ля Рош Аг КРИСТАЛЛИЧЕСКИЕ ПОЛИМОРФНЫЕ ФОРМЫ {3-[5-(4-ХЛОРФЕНИЛ)-1H-ПИРРОЛО[2,3-b]ПИРИДИН-3-КАРБОНИЛ]-2,4-ДИФТОРФЕНИЛ}АМИДА ПРОПАН-1-СУЛЬФОНОВОЙ КИСЛОТЫ
US8329724B2 (en) 2009-08-03 2012-12-11 Hoffmann-La Roche Inc. Process for the manufacture of pharmaceutically active compounds
US8242260B2 (en) * 2009-08-28 2012-08-14 Novartis Ag Compounds and compositions as protein kinase inhibitors
JO3002B1 (ar) 2009-08-28 2016-09-05 Irm Llc مركبات و تركيبات كمثبطات كيناز بروتين
WO2011044414A1 (en) 2009-10-08 2011-04-14 Glaxosmithkline Llc Combination
WO2011044415A1 (en) * 2009-10-08 2011-04-14 Glaxosmithkline Llc Combination
WO2011046894A1 (en) * 2009-10-12 2011-04-21 Glaxosmithkline Llc Combination
DK3560498T3 (da) 2009-10-16 2022-11-14 Novartis Ag Kombination, der omfatter en mek-hæmmer og en b-raf-hæmmer
UA105813C2 (uk) 2009-11-06 2014-06-25 Плексікон, Інк. Сполуки-інгібітори кіназ та фармацевтична композиція (варіанти)
EP2498608A4 (en) * 2009-11-10 2013-04-24 Glaxosmithkline Llc BENZOLSULFONAMIDE THIAZOL AND OXAZOLE COMPOUNDS
WO2011092088A1 (en) * 2010-01-27 2011-08-04 Nerviano Medical Sciences S.R.L. Sulfonamido derivatives of 3,4-diarylpyrazoles as protein kinase inhibitors
US20130096149A1 (en) * 2010-06-25 2013-04-18 Novartis Ag Heteroaryl compounds and compositions as protein kinase inhibitors
JP5938038B2 (ja) * 2010-08-03 2016-06-22 ネルヴィアーノ・メディカル・サイエンシズ・ソチエタ・ア・レスポンサビリタ・リミタータ ピラゾロフェニル−ベンゼンスルホンアミド化合物の誘導体及びその抗腫瘍薬としての使用
US20130172378A1 (en) * 2010-09-14 2013-07-04 Glaxosmithkline Llc Combination of BRAF and VEGF Inhibitors
US20130217710A1 (en) * 2010-11-05 2013-08-22 Glaxosmithkline Intellectual Property (No.2) Limited Methods for treating cancer
US20130231347A1 (en) * 2010-11-19 2013-09-05 Glaxosmithkline Intellectual Property (No.2) Limited Method of treatment with braf inhibitor
TWI505828B (zh) 2010-12-20 2015-11-01 葛蘭素史克智慧財產（第二）有限公司 新穎醫藥組成物
US8691184B2 (en) * 2011-01-25 2014-04-08 The Regents Of The University Of Michigan Bcl-2/Bcl-xL inhibitors and therapeutic methods using the same
PL2672967T3 (pl) 2011-02-07 2019-04-30 Plexxikon Inc Związki i sposoby modulacji kinaz i wskazania ku temu
TWI558702B (zh) 2011-02-21 2016-11-21 普雷辛肯公司 醫藥活性物質的固態形式
CN103403002B (zh) * 2011-02-24 2016-06-22 内尔维阿诺医学科学有限公司 作为激酶抑制剂的噻唑基苯基-苯磺酰氨基衍生物
WO2013019620A2 (en) * 2011-07-29 2013-02-07 Glaxosmithkline Llc Method of treating cancer using combination of braf inhibitor, mek inhibitor, and anti-ctla-4 antibody
US8389723B1 (en) * 2011-08-24 2013-03-05 Glaxosmithkline Llc Deuterated benzene sulfonamide thiazole compounds
CN103917236A (zh) 2011-11-11 2014-07-09 诺华股份有限公司 治疗增生性疾病的方法
DK2782557T3 (en) 2011-11-23 2018-12-10 Array Biopharma Inc PHARMACEUTICAL FORMULATIONS
US20130184280A1 (en) * 2011-12-21 2013-07-18 Telik, Inc. Substituted thiazoles as vegfr2 kinase inhibitors
US9150570B2 (en) 2012-05-31 2015-10-06 Plexxikon Inc. Synthesis of heterocyclic compounds
SI2884979T1 (sl) 2012-08-17 2019-10-30 Hoffmann La Roche Kombinirana zdravljenja melanoma, ki vključujejo dajanje kobimetiniba in vemurafeniba
AU2013313050A1 (en) * 2012-09-04 2015-03-26 Novartis Ag Method of adjuvant cancer treatment
EP2911673A4 (en) * 2012-10-25 2016-05-18 Novartis Ag COMBINATION
EP2917190B1 (en) * 2012-11-09 2017-07-19 Institut National de la Sante et de la Recherche Medicale (INSERM) New benzene sulfonamide thiazole compounds
CN103936728B (zh) * 2013-01-18 2016-08-10 通化济达医药有限公司 噻唑激酶抑制剂
CN103936730A (zh) * 2013-01-22 2014-07-23 通化济达医药有限公司 苯磺酰胺噻唑激酶抑制剂
CN103965170A (zh) * 2013-01-24 2014-08-06 通化济达医药有限公司 苯磺酰胺吡唑激酶抑制剂
CN103965180B (zh) * 2013-01-24 2016-09-07 通化济达医药有限公司 苯磺酰胺噁唑和噻唑激酶抑制剂
US9242969B2 (en) 2013-03-14 2016-01-26 Novartis Ag Biaryl amide compounds as kinase inhibitors
CN104109159A (zh) * 2013-04-17 2014-10-22 杭州普晒医药科技有限公司 苯磺酰胺噻唑化合物的新晶型及其制备方法
TWI634114B (zh) * 2013-05-08 2018-09-01 永恒生物科技公司 作為激酶抑制劑之呋喃酮化合物
KR20160013028A (ko) * 2013-05-30 2016-02-03 플렉시콘, 인코퍼레이티드 키나제 조정을 위한 화합물 및 그에 대한 적응증
HK1216231A1 (zh) 2013-06-03 2016-10-28 Novartis Ag Anti-pd-l1抗体及mek抑制剂及/或braf抑制剂的混合物
CN104540822B (zh) 2013-07-08 2016-08-31 杭州普晒医药科技有限公司 达拉菲尼甲磺酸盐的晶型及其制备方法
WO2015059677A1 (en) 2013-10-26 2015-04-30 Glaxosmithkline Intellectual Property (No.2) Limited Methods of treating cancer
CN103588767B (zh) * 2013-11-20 2016-01-20 苏州明锐医药科技有限公司 达拉菲尼的制备方法
CN103880831A (zh) * 2013-11-25 2014-06-25 镇江圣安医药有限公司 N-(2-氟苯基)-2,6-二氟苯磺酰胺的衍生物及其应用
BR112016011222A2 (pt) 2013-12-12 2017-09-19 Novartis Ag Combinações de trametinib, panitumumab e dabrafenib para o tratamento de câncer
EP3378952B1 (en) 2013-12-28 2020-02-05 Guardant Health, Inc. Methods and systems for detecting genetic variants
WO2015105822A1 (en) * 2014-01-07 2015-07-16 Glaxosmithkline Llc Cancer treatment method
JP6636014B2 (ja) * 2014-09-12 2020-01-29 ノバルティス アーゲー Ｒａｆキナーゼ阻害剤としての化合物および組成物
UY36294A (es) 2014-09-12 2016-04-29 Novartis Ag Compuestos y composiciones como inhibidores de quinasa
WO2016059548A1 (en) 2014-10-13 2016-04-21 Mylan Laboratories Ltd Processes for the preparation of dabrafenib
CN105651927B (zh) * 2014-11-14 2019-12-13 泰州复旦张江药业有限公司 一种伐地昔布/帕瑞昔布有关物质的rt-hplc检测方法
IL294449B2 (en) * 2015-03-31 2024-05-01 Syros Pharmaceuticals Inc Methods for stratifying patients for treatment with retinoic acid alpha receptor agonists
CN106366080A (zh) * 2015-07-21 2017-02-01 重庆大学 一种抗黑色素瘤的化合物及其应用
US10328065B2 (en) * 2015-08-28 2019-06-25 Novartis Ag Pharmaceutical combination comprising the PI3K inhibitor alpelisib and the B-RAF inhibitor dabrafenib; the use of such combination in the treatment or prevention of cancer
JP2018525425A (ja) 2015-08-28 2018-09-06 ノバルティス アーゲー がんを治療または予防するためのリボシクリブとダブラフェニブの組み合わせ
US9868994B2 (en) 2016-04-08 2018-01-16 Syros Pharmaceuticals, Inc. Methods of stratifying patients for treatment with retinoic acid receptor-α agonists
WO2018051306A1 (en) 2016-09-19 2018-03-22 Novartis Ag Therapeutic combinations comprising a raf inhibitor and a erk inhibitor
JP2019532944A (ja) 2016-09-23 2019-11-14 セルイプセ Ｌｉｍｋ介在性疾患における、ｌｉｍキナーゼ阻害剤、医薬組成物および使用方法
US20180125812A1 (en) 2016-11-04 2018-05-10 Emory University Dehydroacetic Acid (DHAA) and Derivative for Uses in Treating Cancer
EP3579872A1 (en) 2017-02-10 2019-12-18 INSERM (Institut National de la Santé et de la Recherche Médicale) Methods and pharmaceutical compositions for the treatment of cancers associated with activation of the mapk pathway
KR20240032157A (ko) 2017-05-02 2024-03-08 노파르티스 아게 병용 요법
CN110831582B (zh) * 2017-07-05 2023-08-11 诺华股份有限公司 药物组合物
EP3732285A1 (en) 2017-12-28 2020-11-04 Tract Pharmaceuticals, Inc. Stem cell culture systems for columnar epithelial stem cells, and uses related thereto
CN108129471A (zh) * 2018-03-20 2018-06-08 韩邦森 一种噻唑取代嘧啶类化合物的合成工艺
CN111936141A (zh) 2018-03-30 2020-11-13 诺华股份有限公司 包含达拉菲尼、曲美替尼和erk抑制剂的三重药物组合
EP3560516A1 (en) 2018-04-27 2019-10-30 Bergen Teknologioverforing AS Combination therapy including beta-sitosterol in combination with at least one of a braf inhibitor, a mek inhibitor or an erk inhibitor and methods and use thereof
WO2019246121A1 (en) * 2018-06-18 2019-12-26 Duke University Compositions and methods for treating disorders characterized with aberrant ras/mapk signaling
WO2020079581A1 (en) 2018-10-16 2020-04-23 Novartis Ag Tumor mutation burden alone or in combination with immune markers as biomarkers for predicting response to targeted therapy
WO2020124397A1 (en) 2018-12-19 2020-06-25 Inventisbio Shanghai Ltd. C-terminal src kinase inhibitors
US20220040324A1 (en) 2018-12-21 2022-02-10 Daiichi Sankyo Company, Limited Combination of antibody-drug conjugate and kinase inhibitor
GB201901507D0 (en) 2019-02-04 2019-03-27 St Georges Hospital Medical School New treatment
MX2021013817A (es) 2019-05-13 2021-12-14 Novartis Ag Nuevas formas cristalinas de n-(3-(2-(2-hidroxietoxi)-6-morfolinop iridin-4-il)-4-metilfenil)-2-(trifluorometil)isonicotinamida como inhibidores de raf para el tratamiento del cancer.
KR20220131229A (ko) * 2019-12-05 2022-09-27 인쎄름 (엥스띠뛰 나씨오날 드 라 쌍떼 에 드 라 흐쉐르슈 메디깔) N-(3-(5-(피리미딘-4-일)티아졸-4-일)페닐)설폰아미드 화합물 및 이의 용도
JP7769388B2 (ja) 2019-12-12 2025-11-13 ティン セラピューティクス，インコーポレイテッド 聴覚損失の予防及び治療のための組成物及び方法
TW202146021A (zh) 2020-02-28 2021-12-16 瑞士商諾華公司 包含達拉菲尼、erk抑制劑和shp2抑制劑之三重藥物組合
AU2021225491A1 (en) 2020-02-28 2022-10-20 Novartis Ag A triple pharmaceutical combination comprising dabrafenib, an Erk inhibitor and a RAF inhibitor
CA3177298C (en) 2020-04-30 2023-11-21 Xile LIU Compounds containing benzosultam as erk inhibitors
CN116887833A (zh) * 2020-12-02 2023-10-13 润新生物公司 某些化学实体、组合物和方法
CN112724052B (zh) * 2021-01-21 2021-09-07 南京艾美斐生物医药科技有限公司 一种gpr101蛋白受体抑制剂及其制备和应用
CN113024384A (zh) * 2021-03-16 2021-06-25 湖南工程学院 一种2-氟-3-硝基苯甲酸中间体原料的合成方法
EP4308935A1 (en) 2021-03-18 2024-01-24 Novartis AG Biomarkers for cancer and methods of use thereof
WO2022259157A1 (en) 2021-06-09 2022-12-15 Novartis Ag A triple pharmaceutical combination comprising dabrafenib, trametinib and a shp2 inhibitor
CN113717053B (zh) * 2021-09-02 2023-10-27 合肥利夫生物科技有限公司 一种酪氨酸激酶抑制剂关键中间体的合成方法
US20250230151A1 (en) * 2021-10-22 2025-07-17 The Board Of Trustees Of The University Of Illinois Compounds for cancers driven by braf mutation
IL315603A (en) * 2022-03-28 2024-11-01 Nikang Therapeutics Inc Sulfonamido derivatives as cycle-dependent KINASE 2 inhibitors
EP4536363A1 (en) * 2022-06-08 2025-04-16 Nikang Therapeutics, Inc. Sulfamide derivatives as cyclin-dependent kinase 2 inhibitors
CN115260179A (zh) * 2022-08-23 2022-11-01 江苏大学 一种2-氨基嘧啶衍生物及其制备方法和应用
WO2024084086A1 (en) * 2022-10-20 2024-04-25 Biper Therapeutics Sas Compositions comprising a benzene sulfonamide thiazole compound
CN115925630B (zh) * 2022-12-15 2025-03-25 金仓(上海)医药生物科技有限公司 一种吡唑硫代酰胺的制备方法
WO2024189184A1 (en) 2023-03-16 2024-09-19 Hua Huang N-[3-(5-(2-aminopyrimidin-4-yl)-2-(tert-butyl)thiazol-4-yl)-2-fluorophenyl]-2,6-difluorobenzenesulfonamide or a pharmaceutically acceptable salt thereof for use in the treatment and/or prevention of cerebral cavernous malformation
AU2023439518A1 (en) 2023-04-06 2025-08-28 Eisai R&D Management Co., Ltd. Pharmaceutical composition for treating tumors
CN119490423A (zh) * 2023-08-15 2025-02-21 沈阳中化农药化工研发有限公司 一种制备2-氟-3-氨基苯甲酸及其酯类化合物的方法
WO2025072462A1 (en) * 2023-09-27 2025-04-03 Nikang Therapeutics, Inc. Sulfonamide derivatives as cyclin-dependent kinase 2 inhibitors
WO2025132388A2 (en) 2023-12-21 2025-06-26 Synthon B.V A process for making dabrafenib
WO2025253311A1 (en) 2024-06-04 2025-12-11 Hetero Labs Limited 1,2-dicarboxamide compounds as kinase inhibitors
CN120393011A (zh) * 2025-04-14 2025-08-01 武汉大学人民医院（湖北省人民医院） Smoc2的诊断和制药用途

Family Cites Families (207)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9015764D0 (en) 1990-07-18 1990-09-05 Fujisawa Pharmaceutical Co Pyrazolopyridine compound and processes for preparation thereof
KR970069028A (ko) 1996-04-01 1997-11-07 김은영 화학색전용 에멀젼의 제조방법
EP0891334A1 (en) 1996-04-03 1999-01-20 Merck & Co., Inc. Inhibitors of farnesyl-protein transferase
AU715606B2 (en) 1996-04-03 2000-02-03 Merck & Co., Inc. Inhibitors of farnesyl-protein transferase
AU716381B2 (en) 1996-04-03 2000-02-24 Merck & Co., Inc. Inhibitors of farnesyl-protein transferase
WO1997036585A1 (en) 1996-04-03 1997-10-09 Merck & Co., Inc. Inhibitors of farnesyl-protein transferase
CA2249665A1 (en) 1996-04-03 1997-10-09 Merck & Co., Inc. Inhibitors of farnesyl-protein transferase
EP0891343A1 (en) 1996-04-03 1999-01-20 Merck & Co., Inc. Inhibitors of farnesyl-protein transferase
GB9609441D0 (en) 1996-05-04 1996-07-10 Zeneca Ltd Process
JP2000514061A (ja) 1996-06-28 2000-10-24 メルク エンド カンパニー インコーポレーテッド フィブリノーゲン受容体拮抗物質
US5755056A (en) 1996-07-15 1998-05-26 Remington Arms Company, Inc. Electronic firearm and process for controlling an electronic firearm
US5877193A (en) 1996-07-19 1999-03-02 Hoffmann-La Roche Inc. Use of N-(4-aryl-thiazol-2-yl)-sulfonamides
DZ2376A1 (fr) 1996-12-19 2002-12-28 Smithkline Beecham Plc Dérivés de sulfonamides nouveaux procédé pour leurpréparation et compositions pharmaceutiques les c ontenant.
AU744475B2 (en) 1997-04-24 2002-02-28 Bristol-Myers Squibb Company Methods and compositions for use in modulating expression of matrix metalloproteinase genes
CA2303152A1 (en) 1997-09-05 1999-03-18 Glaxo Group Limited 2,3-diaryl-pyrazolo[1,5-b]pyridazines derivatives, their preparation and their use as cyclooxygenase 2 (cox-2) inhibitors
BRPI9909191B8 (pt) 1998-03-27 2021-07-06 Janssen Pharmaceutica Nv derivados de pirimidina inibidores do hiv, seu uso e composição farmacêutica que os compreende
US6294558B1 (en) 1999-05-31 2001-09-25 Pfizer Inc. Sulfonylbenzene compounds as anti-inflammatory/analgesic agents
GB9812768D0 (en) 1998-06-13 1998-08-12 Zeneca Ltd Methods
EP1123283B1 (en) 1998-10-22 2004-05-06 F. Hoffmann-La Roche Ag Thiazole-derivatives
CN1263755C (zh) 1998-11-03 2006-07-12 葛兰素集团有限公司 作为选择性cox－2抑制剂的吡唑并吡啶衍生物
AU2201500A (en) * 1999-01-13 2000-08-01 Warner-Lambert Company Benzenesulfonamide derivatives and their use as mek inhibitors
FR2788770B1 (fr) 1999-01-21 2001-02-16 Oreal Nouveaux 2-sulfonylaminophenols cationiques, leur utilisation a titre de coupleur pour la teinture d'oxydation, compositions les comprenant et procedes de teinture
DE69915519T2 (de) 1999-02-27 2005-02-03 Glaxo Group Ltd., Greenford Pyrazolopyridine
GB9904930D0 (en) * 1999-03-04 1999-04-28 Glaxo Group Ltd Thiazoloindolinone compounds
JP2002542280A (ja) 1999-04-27 2002-12-10 スミスクライン・ビーチャム・パブリック・リミテッド・カンパニー 新規な治療
UA71971C2 (en) 1999-06-04 2005-01-17 Agoron Pharmaceuticals Inc Diaminothiazoles, composition based thereon, a method for modulation of protein kinases activity, a method for the treatment of diseases mediated by protein kinases
CA2375909A1 (en) 1999-07-19 2001-01-25 Shionogi & Co., Ltd. Tricyclic compounds bearing acyloxymethoxycarbonyl pendants
WO2001007401A1 (en) 1999-07-23 2001-02-01 Shionogi & Co., Ltd. Tricyclic compounds and drug compositions containing the same
MXPA01013452A (es) 1999-07-23 2002-07-02 Shionogi & Co Inhibodores de diferenciacion th2.
ES2316383T3 (es) 1999-09-17 2009-04-16 Millennium Pharmaceuticals, Inc. Benzamidas e inhibidores relacionados del factor xa.
US6632815B2 (en) 1999-09-17 2003-10-14 Millennium Pharmaceuticals, Inc. Inhibitors of factor Xa
NZ517828A (en) 1999-09-17 2003-10-31 Millennium Pharm Inc Inhibitors having activity against mammalian factor Xa
ES2254238T3 (es) 1999-10-27 2006-06-16 Novartis Ag Compuestos de tiazol e imidazo(4,5-b)piridina y su uso farmaceutico.
HK1050190A1 (zh) 1999-11-22 2003-06-13 Smithkline Beecham Plc 咪唑衍生物和它们做为raf激酶抑制剂的用途
US20020065303A1 (en) 2000-02-01 2002-05-30 Bing-Yan Zhu Bivalent phenylene inhibitors of factor Xa
AU2001250783A1 (en) 2000-02-29 2001-09-12 Cor Therapeutics, Inc. Benzamides and related inhibitors of factor xa
HUP0300382A3 (en) 2000-03-29 2006-11-28 Cyclacel Ltd 2-substituted 4-heteroaryl-pyrimidines and their use in the treatmetn of proliferative disorders and pharmaceutical compositions containing the compounds
EP1273287A1 (en) 2000-04-04 2003-01-08 Shionogi & Co., Ltd. Oily compositions containing highly fat-soluble drugs
WO2001077091A2 (en) 2000-04-05 2001-10-18 Tularik Inc. Ns5b hcv polymerase inhibitors
AU2001244610A1 (en) 2000-04-05 2001-10-23 Shionogi And Co., Ltd. Oil-in-water microemulsions containing tricyclic compounds or preconcentrates thereof
AU2001259242A1 (en) 2000-04-28 2001-11-12 Glaxo Group Limited Process for the preparation of chemical compounds
WO2001087857A1 (fr) 2000-05-16 2001-11-22 Nippon Soda Co., Ltd. Composes de phenyloxazole et fongicides a usage agricole et horticole
ATE272617T1 (de) 2000-06-13 2004-08-15 Lilly Co Eli Sulfonamid-derivate
AU2001268711A1 (en) 2000-06-23 2002-01-08 Bristol-Myers Squibb Pharma Company Heteroaryl-phenyl substituted factor xa inhibitors
PE20020506A1 (es) 2000-08-22 2002-07-09 Glaxo Group Ltd Derivados de pirazol fusionados como inhibidores de la proteina cinasa
US20040067938A1 (en) 2000-09-29 2004-04-08 Penglie Zhang Quaternary amines and related inhibitors of factor xa
DE60112609T2 (de) 2000-12-15 2006-01-19 Glaxo Group Ltd., Greenford Pyrazolopyridine
US7163940B2 (en) 2000-12-15 2007-01-16 Smithkline Beecham Corporation Pyrazolopyridinyl pyrimidine therapeutic compounds
EP1359911A2 (en) 2000-12-29 2003-11-12 Alteon, Inc. Method for treating fibrotic diseases or other indications ivc
WO2002062792A1 (en) 2001-02-02 2002-08-15 Takeda Chemical Industries, Ltd. Jnk inhibitor
AU2002247208A1 (en) 2001-03-05 2002-09-19 Icos Corporation Selective pde3b inhibitors and use of the same in therapy
ES2227451T3 (es) 2001-03-08 2005-04-01 Smithkline Beecham Corporation Derivados de pirazolopiridina.
JP4237497B2 (ja) 2001-03-30 2009-03-11 スミスクライン ビーチャム コーポレーション ピラゾロピリジン類、その調製方法及びその治療用化合物としての使用
JP2004525150A (ja) 2001-03-30 2004-08-19 スミスクライン ビーチャム コーポレーション 治療用化合物としてのピラゾロピリジン類の使用
WO2002083672A1 (en) 2001-04-10 2002-10-24 Smithkline Beecham Corporation Antiviral pyrazolopyridine compounds
HUP0303829A3 (en) 2001-04-16 2006-02-28 Tanabe Seiyaku Co Large conductance calcium-acitvated k channel opener compounds, use thereof and pharmaceutical compositions containing them
EP1385847B1 (en) 2001-04-27 2005-06-01 SmithKline Beecham Corporation Pyrazolo[1,5-a]pyridine derivatives
MXPA03011002A (es) 2001-06-06 2004-10-28 Agouron Pharma Agentes gnrh no peptidicos, composiciones farmaceuticas y procedimientos para su uso y procesos para prepararlos a ellos y a sus intermedios.
IL158667A0 (en) 2001-06-21 2004-05-12 Smithkline Beecham Corp Imidazo [1,2-a] pyridine derivatives for the prophylaxis and treatment of herpes viral infections
AUPR738301A0 (en) 2001-08-30 2001-09-20 Starpharma Limited Chemotherapeutic agents
WO2003022832A1 (en) 2001-09-05 2003-03-20 Smithkline Beecham P.L.C. Pyridylfurans and pyrroles as raf kinase inhibitors
EP1423389B1 (en) 2001-09-07 2007-06-06 SmithKline Beecham Corporation Pyrazolo-pyridines for the treatment of herpes infections
GB0123589D0 (en) 2001-10-01 2001-11-21 Syngenta Participations Ag Organic compounds
ES2262893T3 (es) 2001-10-05 2006-12-01 Smithkline Beecham Corporation Derivados de imidazo-piridina para su uso en el tratamiento de infeccion virica por herpes.
DE10154125A1 (de) 2001-10-25 2003-05-22 Zeiss Carl Semiconductor Mfg Messverfahren und Messsystem zur Vermessung der Abbildungsqualität eines optischen Abbildunsgssystems
AU2002365899B2 (en) 2001-12-04 2007-09-13 Onyx Pharmaceuticals, Inc. RAF-MEK-ERK pathway inhibitors to treat cancer
US7199120B2 (en) 2001-12-11 2007-04-03 Smithkline Beecham Corporation Pyrazolo-pyridine derivatives as antiherpes agents
CA2475206A1 (en) 2002-02-15 2003-08-15 The General Hospital Corporation Map-kinase inhibitors as regulators of tumor-associated antigen expression
EP1485385B1 (en) 2002-03-07 2005-08-17 SmithKline Beecham Corporation Pyrazolopyrimidine and pyrazolotriazine derivatives and pharmaceutical compositions containing them
GB0205693D0 (en) 2002-03-09 2002-04-24 Astrazeneca Ab Chemical compounds
AR039241A1 (es) 2002-04-04 2005-02-16 Biogen Inc Heteroarilos trisustituidos y metodos para su produccion y uso de los mismos
JP2005529889A (ja) 2002-04-26 2005-10-06 ファイザー・プロダクツ・インク ピリミジン−２，４，６−トリオンメタロ−プロテイナーゼ阻害剤
NI200300045A (es) 2002-04-26 2005-07-08 Pfizer Prod Inc Inhibidores de triariloxiariloxipirimidin-2,4,6-triona de metaloproteinasa.
ES2287476T3 (es) 2002-05-10 2007-12-16 Smithkline Beecham Corporation Pirazolopirimidinas sustituidas.
US7015227B2 (en) 2002-06-21 2006-03-21 Cgi Pharmaceuticals, Inc. Certain amino-substituted monocycles as kinase modulators
BR0313160A (pt) 2002-08-08 2005-07-12 Smithkline Beecham Corp Composto, composição farmacêutica, métodos para tratar uma condição e um neoplasmo suscetìvel em um animal em um animal, processo para preparar um composto e uso de um composto
WO2005027710A2 (en) 2002-09-11 2005-03-31 Sequenom, Inc. Methods for identifying subjects at risk of melanoma and treatments thereof
US20040121375A1 (en) 2002-09-30 2004-06-24 Bayer Pharmaceuticals Corporation Methods for prediction and prognosis of cancer, and monitoring cancer therapy
US20040157836A1 (en) * 2002-10-08 2004-08-12 Comess Kenneth M. Sulfonamides having antiangiogenic and anticancer activity
WO2004043368A2 (en) 2002-11-06 2004-05-27 Smithkline Beecham Corporation Sulfonamides
SE0203754D0 (sv) 2002-12-17 2002-12-17 Astrazeneca Ab New compounds
AU2003299750A1 (en) 2002-12-20 2004-07-22 Irm Llc Differential tumor cytotoxocity compounds and compositions
US7144911B2 (en) 2002-12-31 2006-12-05 Deciphera Pharmaceuticals Llc Anti-inflammatory medicaments
US7202257B2 (en) 2003-12-24 2007-04-10 Deciphera Pharmaceuticals, Llc Anti-inflammatory medicaments
US6893159B1 (en) 2003-01-27 2005-05-17 Christopher Eugene Hosmer Lubrication free connection
AU2004218456A1 (en) 2003-02-28 2004-09-16 Encysive Pharmaceuticals Inc. Pyridine, pyrimidine, quinoline, quinazoline, and naphthalene urotensin-II receptor antagonists.
US8178570B2 (en) 2003-04-09 2012-05-15 Exelixis, Inc. Tie-2 modulators and methods of use
JP2006525962A (ja) 2003-04-14 2006-11-16 ノバルティス アクチエンゲゼルシャフト 増殖性疾患を処置するためのおよび増殖性疾患の処置の効果をモニタリングするための方法
EP1633354B1 (en) 2003-04-14 2008-01-23 The Institutes for Pharmaceutical Discovery, LLC N-(((((1,3-thiazol-2-yl)amino)carbonyl)phenyl)sulfonyl)phenylalanine derivatives and related compounds for the treatment of diabetes
MXPA05011536A (es) 2003-04-30 2006-01-23 Inst For Pharm Discovery Inc Acidos carboxilicos substituidos con fenilo como inhibidores de la proteina tirosina fosfatasa-1b.
KR20060006953A (ko) 2003-04-30 2006-01-20 디 인스티튜트스 포 파마슈티컬 디스커버리, 엘엘씨 치환된 카르복실산
US7329680B2 (en) 2003-04-30 2008-02-12 The Institute For Pharmaceutical Discovery, Llc Heterocycle substituted carboxylic acids
EA200501715A1 (ru) 2003-04-30 2006-06-30 ДЗЕ ИНСТИТЬЮТС ФОР ФАРМАСЬЮТИКАЛ ДИСКАВЕРИ, ЭлЭлСи Замещённые аминокарбоновые кислоты в качестве ингибиторов протеинтирозинфосфатазы-1в
SE0301650D0 (sv) 2003-06-04 2003-06-04 Astrazeneca Ab Novel compounds
CA2528003A1 (en) 2003-06-10 2004-12-23 Kalypsys, Inc. Carbonyl compounds as inhibitors of histone deacetylase for the treatment of disease
GB0315111D0 (en) 2003-06-27 2003-07-30 Cancer Rec Tech Ltd Substituted 5-membered ring compounds and their use
GB0315517D0 (en) 2003-07-02 2003-08-06 Barrett Kevin J Earth clamp
WO2005007090A2 (en) 2003-07-03 2005-01-27 President And Fellows Of Harvard College Inhibitors of the map kinase pathway
AU2004261482A1 (en) 2003-07-30 2005-02-10 Cyclacel Limited Pyridinylamino-pyrimidine derivatives as protein kinase inhibitors
WO2005047542A1 (en) 2003-10-16 2005-05-26 The Government Of The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services Treatments for inhibiting development and progression of nevi and melanoma having braf mutations
JP5164380B2 (ja) 2003-10-21 2013-03-21 サイクラセル リミテッド ピリミジン−４−イル−３，４−チオン化合物及び治療におけるその使用
GB0325956D0 (en) 2003-11-06 2003-12-10 Addex Pharmaceuticals Sa Novel compounds
CA2553513A1 (en) 2004-01-22 2005-08-04 Altana Pharma Ag N-4-(6- (heteo) aryl-pyrimidin-4-ylaminophenyl) -bezenesulfonamides as kinase inhibitors
AU2005209485A1 (en) 2004-01-30 2005-08-11 Ab Science 2-(3-substituted-aryl)amino-4-aryl-thiazoles as tyrosine kinase inhibitors
EP1723102A2 (en) 2004-03-11 2006-11-22 Elan Pharmaceuticals, Inc. N-substituted benzene sulfonamides
US20090253908A1 (en) 2004-03-11 2009-10-08 Glaxo Group Limited Novel m3 muscarinic acetylchoine receptor antagonists
MXPA06010667A (es) 2004-03-19 2007-07-04 Penn State Res Found Metodos combinatorios y composiciones para el tratamiento de melanoma.
DE102004018198A1 (de) 2004-04-15 2005-11-03 Merck Patent Gmbh Sulfonamide
WO2005113490A1 (en) 2004-05-21 2005-12-01 Icagen, Inc. Sulfone-containing prodrugs
GB0411791D0 (en) 2004-05-26 2004-06-30 Cyclacel Ltd Compounds
JP4163738B2 (ja) 2004-06-11 2008-10-08 日本たばこ産業株式会社 癌の治療用の５−アミノ−２，４，７−トリオキソ−３，４，７，８−テトラヒドロ−２Ｈ−ピリド’２，３−ｄ！ピリミジン誘導体及び関連化合物
JP2007223903A (ja) 2004-07-09 2007-09-06 Takeda Chem Ind Ltd 新規な固体分散体およびその製造方法
RU2007107349A (ru) * 2004-07-28 2008-09-10 Глэксо Груп Лимитед (GB) Пиперазиновые производные, применение для лечения желудочно-кишечных расстройств
ES2401138T3 (es) 2004-08-13 2013-04-17 Genentech, Inc. Inhibidores basados en tiazol de enzimas que usan ATP
AU2005280167A1 (en) 2004-08-31 2006-03-09 Biogen Idec Ma Inc. Pyrimidinylpyrazoles as TGF-beta inhibitors
GB0420424D0 (en) 2004-09-14 2004-10-20 Ionix Pharmaceuticals Ltd Therapeutic compounds
JP4810814B2 (ja) 2004-09-15 2011-11-09 オムロン株式会社 光学シート及び面光源装置
EP1640018A1 (en) 2004-09-24 2006-03-29 Universität Zürich Combinational therapy for treating cancer
KR20070057252A (ko) 2004-09-24 2007-06-04 얀센 파마슈티카 엔.브이. 설폰아미드 화합물
AU2005295734A1 (en) 2004-10-15 2006-04-27 Biogen Idec Ma Inc. Methods of treating vascular injuries
JP2008518036A (ja) 2004-10-26 2008-05-29 サード−オーダー ナノテクノロジーズ， インク． 非線形光学デバイス用の三環式スペーサーシステム
JP2008518937A (ja) 2004-10-28 2008-06-05 ジ インスティチューツ フォー ファーマシューティカル ディスカバリー、エルエルシー 置換カルボン酸
JP2008518926A (ja) 2004-10-28 2008-06-05 ジ インスティチューツ フォー ファーマシューティカル ディスカバリー、エルエルシー 置換フェニルアルカン酸
US20060134068A1 (en) 2004-11-09 2006-06-22 Mount Sinai School Of Medicine Of New York University Treatment of cancer by simultaneous inhibiton of BRAF and restoration or mimicry of p16INK4A activity
ATE542817T1 (de) 2004-11-10 2012-02-15 Ono Pharmaceutical Co Stickstoffhaltige heterocyclische verbindung und deren pharmazeutische verwendung
WO2006055553A2 (en) 2004-11-15 2006-05-26 Glaxo Group Limited Novel m3 muscarinic acetylcholine receptor antagonists
US20090142279A1 (en) 2004-11-15 2009-06-04 Budzik Brian W Novel m3 muscarinic acetylcholine receptor antagonists
CA2588766A1 (en) 2004-11-18 2006-05-26 The Institutes For Pharmaceutical Discovery, Llc Heterocycle substituted carboxylic acids
WO2006055725A2 (en) 2004-11-18 2006-05-26 The Institutes For Pharmaceutical Discovery, Llc Substituted amino acids as protein tyrosine phosphatase inhibitors
CA2587566A1 (en) 2004-11-18 2006-05-26 The Institutes For Pharmaceutical Discovery, Llc Heterocyclylbiphenyl derivates as protein tyrosine phosphatase inhibitors
WO2006064375A2 (en) 2004-12-16 2006-06-22 Ab Science Aminoaryl substituted five-membered ring heterocyclic compounds for the treatment of diseases
WO2006068826A2 (en) 2004-12-21 2006-06-29 Smithkline Beecham Corporation 2-pyrimidinyl pyrazolopyridine erbb kinase inhibitors
US7812022B2 (en) 2004-12-21 2010-10-12 Glaxosmithkline Llc 2-pyrimidinyl pyrazolopyridine ErbB kinase inhibitors
DK2354126T3 (da) 2005-01-14 2014-01-13 Chemocentryx Inc Heteroarylsulfonamider og ccr2
US7622583B2 (en) 2005-01-14 2009-11-24 Chemocentryx, Inc. Heteroaryl sulfonamides and CCR2
EP2527337A1 (en) 2005-04-14 2012-11-28 Bristol-Myers Squibb Company Inhibitors of 11-beta hydroxysteroid dehydrogenase type I
GB0510139D0 (en) 2005-05-18 2005-06-22 Addex Pharmaceuticals Sa Novel compounds B1
JP5388574B2 (ja) 2005-05-31 2014-01-15 バーテックス ファーマシューティカルズ インコーポレイテッド イオンチャネルのモジュレーターとして有用なヘテロ環式類
PL2395004T3 (pl) 2005-06-22 2016-08-31 Plexxikon Inc Pochodne pirolo[2,3-b]pirydyny jako inhibitory kinazy białkowej
EP1899695B8 (en) 2005-06-30 2012-06-27 LED Roadway Lighting Ltd. Method and system for luminance characterization
GB0513702D0 (en) 2005-07-04 2005-08-10 Sterix Ltd Compound
US10144970B2 (en) 2005-07-13 2018-12-04 University Of Utah Research Foundation Methods and compositions related to a BRAF mutation and microsatellite stability
WO2007013997A2 (en) 2005-07-22 2007-02-01 H. Lee Moffitt Cancer Center And Research Institute Inhibition of the raf/mek/p-erk pathway for treating cancer
KR101289995B1 (ko) 2005-09-27 2013-07-26 시오노기 앤드 컴파니, 리미티드 Ｐｇｄ2 수용체 길항제 활성을 갖는 설폰아마이드 유도체
US7910742B2 (en) 2005-09-29 2011-03-22 Abbott Laboratories Survivin inhibitors
AU2006298132A1 (en) 2005-10-03 2007-04-12 Ono Pharmaceutical Co., Ltd. Nitrogen-containing heterocyclic compound and pharmaceutical application thereof
AU2006311523A1 (en) 2005-11-07 2007-05-18 Irm Llc Oxazole and thiazole PPAR modulator
KR20080059635A (ko) 2005-11-07 2008-06-30 아이알엠 엘엘씨 Ｐｐａｒ 조절제로서의 화합물 및 조성물
TW200736260A (en) 2005-11-10 2007-10-01 Smithkline Beecham Corp Inhibitors of Akt activity
EP1951716B1 (en) 2005-11-16 2011-05-04 Vertex Pharmaceuticals, Inc. Aminopyrimidines useful as kinase inhibitors
US7625896B2 (en) 2005-11-25 2009-12-01 Hoffman-La Roche Inc. Pyridylsulfonamide derivatives
US7807673B2 (en) 2005-12-05 2010-10-05 Glaxosmithkline Llc 2-pyrimidinyl pyrazolopyridine ErbB kinase inhibitors
US20070135368A1 (en) 2005-12-09 2007-06-14 Knapp Pamela E Cell-to-cell transmission of siRNA induced gene silencing in mammalian cells
CN101365686A (zh) 2005-12-21 2009-02-11 沃泰克斯药物股份有限公司 作为离子通道调节剂的杂环衍生物
EP1981884B1 (en) 2006-01-18 2012-06-13 Amgen, Inc Thiazole compounds as protein kinase b (pkb) inhibitors
US7560551B2 (en) 2006-01-23 2009-07-14 Amgen Inc. Aurora kinase modulators and method of use
EA018128B1 (ru) 2006-01-23 2013-05-30 Амген Инк. Модуляторы аурора киназы, способы их получения и их применение
WO2007087429A2 (en) 2006-01-25 2007-08-02 Synta Pharmaceuticals Corp. Phenyl and pyridyl compounds for inflammation and immune-related uses
WO2008054454A2 (en) 2006-02-10 2008-05-08 Transtech Pharma, Inc. Nitrogen-containing heterocycle derivatives, pharmaceutical compositions, and methods of use thereof as antiviral agents
PE20080176A1 (es) * 2006-03-31 2008-04-25 Glaxo Group Ltd Compuestos de arilpiperazina sulfonamida como agonista de los receptores de secretagogos de la hormona de crecimiento (ghs)
US7351434B2 (en) 2006-04-07 2008-04-01 Academia Sinica Therapeutic Gastrodia extracts
EP2007716A1 (en) * 2006-04-13 2008-12-31 Glaxo Group Limited Aryl and heteroaryl sulphonamides as growth hormone secretagogue receptor agonists
CA2649512A1 (en) 2006-04-20 2007-11-01 Janssen Pharmaceutica N.V. C-fms kinase inhibitors
ES2352320T3 (es) 2006-05-12 2011-02-17 Ab Science Nuevo procedimiento para la síntesis de compuestos de 2-aminoxazol.
WO2008002490A2 (en) 2006-06-23 2008-01-03 Radius Health, Inc. Treatment of vasomotor symptoms with selective estrogen receptor modulators
WO2008013660A2 (en) 2006-07-07 2008-01-31 Biostratum, Inc. Inhibitors of advanced glycation end products
JP5153773B2 (ja) 2006-07-07 2013-02-27 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング フェニル置換ヘテロアリール誘導体及び抗癌剤としてのその使用
WO2008013928A2 (en) 2006-07-28 2008-01-31 Biogen Idec Ma Inc. Treatment of cancer with interferon gene delivery in combination with a tgf-beta inhibitor
DK2420494T3 (en) * 2006-08-16 2015-01-12 J David Gladstone Inst A Testamentary Trust Established Under The Will Of J David Gladstone Use of thiadiazole compounds as inhibitors of kynurenine 3-monooxygenase
EP2054397B1 (en) 2006-08-16 2015-10-07 The J. David Gladstone Institutes, A Testamentary Trust Established under The Will of J. David Gladstone Small molecule inhibitors of kynurenine-3-monooxygenase
GB0622202D0 (en) 2006-11-07 2006-12-20 Addex Pharmaceuticals Sa Novel compounds
NZ578180A (en) 2006-12-08 2012-02-24 Millennium Pharm Inc Unit dose formulations and methods of treating thrombosis with an oral factor xa inhibitor
KR20090088962A (ko) 2006-12-15 2009-08-20 바이엘 쉐링 파마 악티엔게젤샤프트 ３-ｈ-피라졸로피리딘 및 그의 염, 이를 포함하는 제약 조성물, 이의 제조 방법 및 이의 용도
AU2008214095B2 (en) 2007-02-02 2014-07-10 Baylor College Of Medicine Compositions and methods for the treatment of metabolic disorders
JP2010528585A (ja) 2007-02-26 2010-08-26 ジョン ウェイン キャンサー インスティテュート 癌の診断および治療におけるｂ−ｒａｆｄｎａ変異の有用性
US8338437B2 (en) 2007-02-28 2012-12-25 Methylgene Inc. Amines as small molecule inhibitors
RU2009137190A (ru) 2007-03-08 2011-04-20 Плексксикон, Инк. (Us) Соединения, обладающие активностью в отношении ppar
WO2008120004A1 (en) 2007-04-02 2008-10-09 Astrazeneca Ab Combination of a mek- inhibitor and a b-raf inhibitor for the treatment of cancer
WO2008129288A2 (en) 2007-04-19 2008-10-30 Boehringer Ingelheim International Gmbh Disulfonamides useful in the treatment of inflammation
US7592342B2 (en) 2007-05-10 2009-09-22 Smithkline Beecham Corporation Quinoxaline derivatives as PI3 kinase inhibitors
WO2008141275A1 (en) 2007-05-11 2008-11-20 The Johns Hopkins University Biomarkers for melanoma
CN101932580B (zh) * 2007-06-01 2013-05-22 葛兰素史密丝克莱恩有限责任公司 咪唑并吡啶激酶抑制剂
JP5539864B2 (ja) 2007-06-12 2014-07-02 アカオゲン，インコーポレーテッド 抗菌剤
JP2010531850A (ja) 2007-07-02 2010-09-30 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング 新規化合物
WO2009010871A2 (en) 2007-07-13 2009-01-22 Addex Pharma S.A. Pyrazole derivatives as antagonists of adenosine a3 receptor
WO2009011850A2 (en) 2007-07-16 2009-01-22 Abbott Laboratories Novel therapeutic compounds
MX2010000617A (es) 2007-07-17 2010-05-17 Plexxikon Inc Compuestos y metodos para modulacion de cinasa, e indicaciones de estos.
WO2009036188A2 (en) 2007-09-11 2009-03-19 University Of Massachusetts Insulin-like growth factor binding protein 7 for treatment of cancer
CL2008002793A1 (es) 2007-09-20 2009-09-04 Cgi Pharmaceuticals Inc Compuestos derivados de amidas sustituidas, inhibidores de la actividad de btk; composicion farmaceutica que los comprende; utiles en el tratamiento del cancer, trastornos oseos, enfermedades autoinmunes, entre otras
WO2009062122A1 (en) 2007-11-09 2009-05-14 John Wayne Cancer Institute Utility of ret mutant in diagnosis and treatment of melanoma
GB0722680D0 (en) 2007-11-19 2007-12-27 Topotarget As Therapeutic compounds and their use
WO2009076140A1 (en) 2007-12-13 2009-06-18 Smithkline Beecham Corporation Thiazole and oxazole kinase inhibitors
DK2234966T3 (da) 2007-12-18 2014-01-06 Sanofi Sa Azetidinderivater, fremstilling og terapeutisk anvendelse heraf
JPWO2009096198A1 (ja) 2008-02-01 2011-05-26 一般社団法人ファルマＩｐ 新規ビアリール誘導体
US8653045B2 (en) 2008-02-05 2014-02-18 The Johns Hopkins University Induction of thyroid iodide-handling gene expression in human cancers
CA2714232A1 (en) 2008-02-05 2009-08-13 Pfizer Inc. Pyridinyl amides for the treatment of cns and metabolic disorders
US20090275546A1 (en) 2008-04-10 2009-11-05 Istituto Superiore Di Sanita Diagnostic tests and personalized treatment regimes for cancer stem cells
US8198284B2 (en) 2008-04-30 2012-06-12 National Health Research Institutes Treatment of neurodegenerative disorders with thiourea compounds
UA103319C2 (en) * 2008-05-06 2013-10-10 Глаксосмитклайн Ллк Thiazole- and oxazole-benzene sulfonamide compounds
US8133884B2 (en) 2008-05-06 2012-03-13 Bristol-Myers Squibb Company Compounds for the treatment of hepatitis C
WO2010005922A1 (en) 2008-07-07 2010-01-14 Fasgen, Inc. Novel compounds, pharmaceutical compositions containing same, methods of use for same, and methods for preparing same
AU2009273197B2 (en) 2008-07-24 2014-01-16 Nerviano Medical Sciences S.R.L. 3,4-diarylpyrazoles as protein kinase inhibitors
AU2009279787B2 (en) 2008-08-04 2014-05-29 Chdi Foundation, Inc. Certain kynurenine-3-monooxygenase inhibitors, pharmaceutical compositions, and methods of use thereof
WO2010018458A2 (en) 2008-08-12 2010-02-18 Crystalgenomics, Inc. Phenol derivatives and methods of use thereof
US20110319415A1 (en) 2008-08-18 2011-12-29 Universit+e,uml a+ee t zu K+e,uml o+ee ln Susceptibility to HSP90-Inhibitors
GB0815947D0 (en) 2008-09-02 2008-10-08 Univ Dundee Compounds
US8499305B2 (en) 2010-10-15 2013-07-30 Via Technologies, Inc. Systems and methods for performing multi-program general purpose shader kickoff

Also Published As

Publication number Publication date
DK2282636T3 (en) 2016-05-02
CA2723396C (en) 2013-09-10
EA019349B1 (ru) 2014-03-31
AU2009244491A1 (en) 2009-11-12
MY155317A (en) 2015-09-30
CN102083312A (zh) 2011-06-01
EP3106462A1 (en) 2016-12-21
EP2282636A2 (en) 2011-02-16
IL209018A (en) 2015-08-31
EA201001680A1 (ru) 2011-06-30
TWI432430B (zh) 2014-04-01
EP2282636B1 (en) 2016-03-23
TW200951130A (en) 2009-12-16
JP2011519940A (ja) 2011-07-14
ES2576684T3 (es) 2016-07-08
IL209018A0 (en) 2011-01-31
CL2009001065A1 (es) 2010-12-31
KR101628746B1 (ko) 2016-06-13
US9233956B2 (en) 2016-01-12
US8415345B2 (en) 2013-04-09
US20140080851A1 (en) 2014-03-20
ZA201007960B (en) 2012-04-25
JP5426664B2 (ja) 2014-02-26
CO6321189A2 (es) 2011-09-20
DOP2010000326A (es) 2010-12-15
NZ588970A (en) 2012-06-29
HRP20160447T1 (hr) 2016-05-20
WO2009137391A2 (en) 2009-11-12
SI2282636T1 (sl) 2016-06-30
KR20110013456A (ko) 2011-02-09
BRPI0912541B1 (pt) 2021-05-11
WO2009137391A3 (en) 2009-12-30
CA2723396A1 (en) 2009-11-12
AR071617A1 (es) 2010-06-30
BRPI0912541B8 (pt) 2021-05-25
US20160068523A1 (en) 2016-03-10
US8642759B2 (en) 2014-02-04
CN102083312B (zh) 2014-08-27
UA103319C2 (en) 2013-10-10
RS54725B1 (sr) 2016-10-31
UY31806A (es) 2009-12-14
PE20091952A1 (es) 2010-01-21
US20110172215A1 (en) 2011-07-14
PL2282636T3 (pl) 2016-08-31
AU2009244491B2 (en) 2014-08-07
MA32369B1 (ar) 2011-06-01
EP2282636A4 (en) 2012-06-13
BRPI0912541A2 (pt) 2020-08-04
CY1117615T1 (el) 2017-04-26
US20170073341A1 (en) 2017-03-16
US20090298815A1 (en) 2009-12-03
HUE028820T2 (en) 2017-01-30
HK1147907A1 (zh) 2011-08-26
MX2010012074A (es) 2011-03-21
US7994185B2 (en) 2011-08-09
US20130144055A1 (en) 2013-06-06
SG190624A1 (en) 2013-06-28

Similar Documents

Publication Publication Date Title
JO3408B1 (ar) مركبات بترين سلفون اميد ثيازول و أوكسازول
TW200800967A (en) Benzimidazole thiophene compounds
MY153915A (en) Organic compounds
MX2009000884A (es) Derivados de piridizinona.
BRPI0922364A2 (pt) Composto, composição farmacêutica e uso de um composto
MX2011011661A (es) Compuestos 1-cianoetilheterociclilcarboxamida sustituidos 750.
CL2009000349A1 (es) Compuestos derivados de 4,5-dihidro-oxazol-2-ilamina; procedimiento de preparacion; composicion farmaceutica; y su uso para el tratamiento de la enfermedad de alzheimer.
EA201170295A1 (ru) ИНГИБИТОРЫ сМЕТ
EA201001205A1 (ru) Соединения, содержащие циклобутоксигруппу
TW200800999A (en) Novel compounds
MX354402B (es) Inhibidores de molecula pequeña del dominio de homologia de pleckstrin y metodos para usar los mismos.
EA201401193A1 (ru) Триарильные соединения и композиции, их содержащие
EA201101116A1 (ru) Фармацевтические композиции, включающие производные 2-оксо-1-пирролидина
EA201101118A1 (ru) Фармацевтические композиции, включающие производные 2-оксо-1-пирролидина
TW200942524A (en) Novel aminomethyl benzene derivatives
PT2280706E (pt) Composições compreendendo derivados de benzeno que activam lipase de lipoproteína
TW200738659A (en) Novel compounds
EA201001855A1 (ru) Соединения, содержащие циклобутоксигруппу
AU2011279845A8 (en) Novel pyrrolidine derived beta 3 adrenergic receptor agonists
ATE459620T1 (de) Benzimidazolthiophenverbindungen als plk- modulatoren
TW200734306A (en) Novel compounds, their preparation and use
NO20074528L (no) Substituerte pyrroler, sammensetninger, fremgangsmate for fremstilling og anvendelse av samme
SG151306A1 (en) Novel benzothiazoles and the use thereof as medicaments
TW200738244A (en) 20-Alkyl, gemini vitamin D3 compounds and methods of use thereof
UA92180C2 (en) Benzimidazole thiophene compounds as plk inhibitors